This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Paladin Labs Inc. announces approval of Wakix in C...
News

Paladin Labs Inc. announces approval of Wakix in Canada for the treatment of excessive daytime sleepiness or cataplexy.

Read time: 1 mins
Published:17th Jun 2021
Paladin Labs Inc., a subsidiary of Endo International plc announced Health Canada's approval of Wakix (pitolisant) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.

Paladin plans to work collaboratively with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS) to ensure patients have access to Wakix as soon as possible.

In 2018 Endo Ventures Limited, a subsidiary of Endo International plc, entered into an agreement with Bioprojet SCR to register, commercialize, and distribute pitolisant on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, is commercializing pitolisant in Canada.

Condition: Sleeping Disorders
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.